ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3036% below fair value
$13.68+0.44 (+3.32%)
Close on Nov 13, 2026Market cap $3.06BP/E 17.8Yield –
ADMA Biologics gross margin
Gross margin is gross profit as a percentage of revenue.
ADMA Biologics's gross margin for the twelve months ending Sep 30, 2026 was 68.5%. For fiscal 2025 it was 57.4%, against 51.5% the year before. The highest annual figure on record is 72.7% in fiscal 2011.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 57.4% | +5.9 |
| FY2024 | Dec 31, 2024 | 51.5% | +17.0 |
| FY2023 | Dec 31, 2023 | 34.4% | +11.6 |
| FY2022 | Dec 31, 2022 | 22.9% | +21.4 |
| FY2021 | Dec 31, 2021 | 1.4% | +46.6 |
| FY2020 | Dec 31, 2020 | -45.2% | −10.6 |
| FY2019 | Dec 31, 2019 | -34.6% | +113.8 |
| FY2018 | Dec 31, 2018 | -148.4% | −120.3 |
| FY2017 | Dec 31, 2017 | -28.1% | −68.5 |
| FY2016 | Dec 31, 2016 | 40.3% | +0.4 |
| FY2015 | Dec 31, 2015 | 39.9% | +3.2 |
| FY2014 | Dec 31, 2014 | 36.7% | +2.7 |
| FY2013 | Dec 31, 2013 | 34.0% | −6.1 |
| FY2012 | Dec 31, 2012 | 40.2% | −32.6 |
| FY2011 | Dec 31, 2011 | 72.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 70.8% | +14.5 |
| Q2 FY2026 | Jun 30, 2026 | 69.4% | +14.2 |
| Q1 FY2026 | Mar 31, 2026 | 70.5% | +17.3 |
| Q4 FY2025 | Dec 31, 2025 | 63.8% | +9.9 |
| Q3 FY2025 | Sep 30, 2025 | 56.3% | +6.6 |
| Q2 FY2025 | Jun 30, 2025 | 55.1% | +1.5 |
| Q1 FY2025 | Mar 31, 2025 | 53.2% | +5.5 |
| Q4 FY2024 | Dec 31, 2024 | 53.9% | +11.8 |
| Q3 FY2024 | Sep 30, 2024 | 49.8% | +13.1 |
| Q2 FY2024 | Jun 30, 2024 | 53.6% | +25.8 |
| Q1 FY2024 | Mar 31, 2024 | 47.8% | +18.8 |
| Q4 FY2023 | Dec 31, 2023 | 42.1% | +13.7 |
| Q3 FY2023 | Sep 30, 2023 | 36.6% | +13.1 |
| Q2 FY2023 | Jun 30, 2023 | 27.8% | +4.8 |
| Q1 FY2023 | Mar 31, 2023 | 29.0% | +16.4 |
| Q4 FY2022 | Dec 31, 2022 | 28.4% | +15.1 |
| Q3 FY2022 | Sep 30, 2022 | 23.5% | +21.6 |
| Q2 FY2022 | Jun 30, 2022 | 22.9% | +28.5 |
| Q1 FY2022 | Mar 31, 2022 | 12.6% | +23.3 |
| Q4 FY2021 | Dec 31, 2021 | 13.3% | +50.2 |
| Q3 FY2021 | Sep 30, 2021 | 1.9% | +17.2 |
| Q2 FY2021 | Jun 30, 2021 | -5.6% | +67.7 |
| Q1 FY2021 | Mar 31, 2021 | -10.7% | +54.3 |
| Q4 FY2020 | Dec 31, 2020 | -36.9% | −39.8 |
| Q3 FY2020 | Sep 30, 2020 | -15.4% | −5.8 |
| Q2 FY2020 | Jun 30, 2020 | -73.3% | −13.4 |
| Q1 FY2020 | Mar 31, 2020 | -65.0% | +101.5 |
| Q4 FY2019 | Dec 31, 2019 | 2.9% | +177.5 |
| Q3 FY2019 | Sep 30, 2019 | -9.6% | +107.0 |
| Q2 FY2019 | Jun 30, 2019 | -59.9% | +47.2 |
| Q1 FY2019 | Mar 31, 2019 | -166.5% | +36.3 |
| Q4 FY2018 | Dec 31, 2018 | -174.7% | −175.3 |
| Q3 FY2018 | Sep 30, 2018 | -116.6% | +22.1 |
| Q2 FY2018 | Jun 30, 2018 | -107.1% | −79.6 |
| Q1 FY2018 | Mar 31, 2018 | -202.9% | −241.4 |
| Q4 FY2017 | Dec 31, 2017 | 0.7% | −38.8 |
| Q3 FY2017 | Sep 30, 2017 | -138.7% | – |
| Q2 FY2017 | Jun 30, 2017 | -27.5% | – |
| Q1 FY2017 | Mar 31, 2017 | 38.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 39.5% | – |
See a number that looks wrong?